Evan Wang
Stock Analyst at Guggenheim
(n/a)
# 4,719
Out of 5,127 analysts
6
Total ratings
n/a
Success rate
-59.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Reiterates: Neutral | n/a | $78.09 | - | 3 | Dec 12, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $2.40 | +275.00% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $9.89 | +71.89% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $35.89 | - | 1 | Apr 26, 2023 |
Spruce Biosciences
Dec 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $78.09
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $2.40
Upside: +275.00%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $9.89
Upside: +71.89%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $35.89
Upside: -